Intraoperative concerns when a liver recipient is critically ill
Andre M. De Wolf – 13 February 2012
Metabolism and liver transplantation: Review of perioperative issues
William T. Merritt – 13 February 2012
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B‐unfavorable genotype patients: Impaired viral kinetics and therapeutic response
Susanna Naggie, Anu Osinusi, Antonios Katsounas, Richard Lempicki, Eva Herrmann, Alexander J. Thompson, Paul J. Clark, Keyur Patel, Andrew J. Muir, John G. McHutchison, Joerg F. Schlaak, Martin Trippler, Bhavana Shivakumar, Henry Masur, Michael A. Polis, Shyam Kottilil – 13 February 2012 – Recent studies have shown that a single‐nucleotide polymorphism upstream of the interleukin‐28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)‐infected patients treated with pegylated interferon (PEG‐IFN)/ribavirin.
Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus–mediated liver disease posttransplantation
Deborah L. Diamond, Alexei L. Krasnoselsky, Kristin E. Burnum, Matthew E. Monroe, Bobbie‐Jo Webb‐Robertson, Jason E. McDermott, Matthew M. Yeh, Jose Felipe Golib Dzib, Nathan Susnow, Susan Strom, Sean C. Proll, Sarah E. Belisle, David E. Purdy, Angela L. Rasmussen, Kathie‐Anne Walters, Jon M. Jacobs, Marina A. Gritsenko, David G. Camp, Renuka Bhattacharya, James D. Perkins, Robert L. Carithers, Iris W. Liou, Anne M. Larson, Arndt Benecke, Katrina M. Waters, Richard D. Smith, Michael G.
Multiple organ failure during critical illness: How organ failure influences outcome in liver disease and liver transplantation
Kenneth Baker, Stanley A. Nasraway – 13 February 2012
Bioartificial liver in the treatment of hepatic failure
Willis C. Maddrey – 13 February 2012
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection
Norah A. Terrault, Michelle E. Roland, Thomas Schiano, Lorna Dove, Michael T. Wong, Fred Poordad, Margaret V. Ragni, Burc Barin, David Simon, Kim M. Olthoff, Lynt Johnson, Valentina Stosor, Dushyantha Jayaweera, John Fung, Kenneth E. Sherman, Aruna Subramanian, J. Michael Millis, Douglas Slakey, Carl L. Berg, Laurie Carlson, Linda Ferrell, Donald M. Stablein, Jonah Odim, Lawrence Fox, Peter G.
Safety of anidulafungin in solid organ transplant recipients
J.M. Aguado, E. Varo, P. Usetti, J.C. Pozo, A. Moreno, M. Catalán, O. Len, M. Blanes, A. Solé, P. Muñoz, M. Montejo, the TOSCANA Study Group – 12 February 2012 – The aim of this study was the evaluation of the safety of anidulafungin in adult solid organ transplantation (SOT) recipients. During the study period (14 months), we included all consecutive SOT recipients from 14 centers who received anidulafungin for at least 48 hours for the treatment of invasive fungal infections (IFIs) or as prophylaxis. Relevant clinical and analytical information on clinical charts was reviewed.
Hepatocellular carcinoma and model for end‐stage liver disease exceptions: The more we understand, the more challenging the allocation gets
Patrick G. Northup, Carl L. Berg – 10 February 2012
Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype‐specific manner
Paul J. Clark, Alexander J. Thompson, David M. Vock, Lisa E. Kratz, Adviye A. Tolun, Andrew J. Muir, John G. McHutchison, Mani Subramanian, David M. Millington, Richard I. Kelley, Keyur Patel – 9 February 2012 – Hepatitis C virus (HCV) subverts host cholesterol metabolism for key processes in its lifecycle. How this interference results in the frequently observed, genotype‐dependent clinical sequelae of hypocholesterolemia, hepatic steatosis, and insulin resistance (IR) remains incompletely understood.